Motoshi Kawashima

Longitudinal analysis of premotor anthropometric and serological markers of Parkinson’s disease

M. Katsuno, Hirohisa Watanabe, Yasuhiro Tanaka, 2020, Scientific Reports.

Efficacy and safety of leuprorelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials

G. Sobue, M. Katsuno, A. Hirakawa, 2019, Journal of Neurology.

Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial

S. Tsuji, G. Sobue, M. Morita, 2010, The Lancet Neurology.

Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy

G. Sobue, N. Atsuta, M. Katsuno, 2009, Annals of neurology.

Clinico-imaging features of subjects at risk of Lewy body disease in NaT-PROBE baseline analysis

H. Matsuda, Y. Arahata, Y. Washimi, 2023, NPJ Parkinson's disease.

The profile of motor unit number estimation (MUNE) in spinal and bulbar muscular atrophy

G. Sobue, M. Katsuno, Tomohiko Nakamura, 2009, Journal of Neurology, Neurosurgery & Psychiatry.

Walking capacity evaluated by the 6‐minute walk test in spinal and bulbar muscular atrophy

G. Sobue, N. Atsuta, M. Katsuno, 2008, Muscle & nerve.

Subjects at risk of Parkinson’s disease in health checkup examinees: cross-sectional analysis of baseline data of the NaT-PROBE study

Y. Arahata, Y. Washimi, M. Katsuno, 2020, Journal of Neurology.

Molecular genetics and biomarkers of polyglutamine diseases.

G. Sobue, M. Katsuno, H. Adachi, 2008, Current molecular medicine.